Let the Bids Begin! Pros See Higher Onyx Offers

Amgen's allegedly low-ball offer to buy Onyx Pharmaceuticals has set off a potential bidding war that could score much-bigger bucks for the cancer drugmaker while leaving biotech behemoth Amgen looking like a groom left behind at the altar, analysts said.